Step 1 topics → Hematology and Oncology → Multiple Myeloma

Multiple Myeloma

USMLE Step 1 trap: Assumes myeloma is always IgG, missing IgA and light-chain-only variants. Multiple myeloma most commonly produces IgG (~55%), but IgA (~25%) and light-chain-only disease are well-tested variants with distinct features.

Multiple myeloma is a malignant clonal plasma cell disorder that produces a monoclonal immunoglobulin (M protein), causes end-organ damage, and is one of the highest-yield hematologic malignancies on USMLE Step 1. The classic presentation is an older adult with bone pain, renal failure, anemia, and hypercalcemia — the CRAB criteria. The most common mechanistic error: assuming myeloma hypercalcemia is PTH-driven. PTH would be suppressed in hypercalcemia. The real mechanism is cytokine-mediated osteoclast activation (RANKL, IL-1, IL-6), which explains both the elevated calcium and the lytic bone lesions without osteoblastic reaction. The exam tests this from multiple angles — diagnostic criteria, CRAB mechanisms, smear findings, and complication identification.

What makes this topic tricky is that students memorize the surface facts but build the wrong causal models. For example, many students assume myeloma always produces IgG and that hypercalcemia is PTH-driven — both are wrong and both show up on USMLE Step 1 as wrong answer choices designed to trap you. The Ig class matters because IgA and light-chain-only variants have different serum vs. urine findings, and the hypercalcemia mechanism (osteoclast activation via RANKL/IL-1/IL-6, not PTH) is explicitly tested in mechanistic questions.

The other major pitfall is misunderstanding which complications come from which mechanism. Students conflate marrow infiltration with the primary immune defect, or assume rouleaux on smear is a myeloma-specific finding. It's not — rouleaux just means elevated proteins causing RBC stacking, which occurs in any hyperglobulinemic state. Building the right mechanistic framework — clonal plasma cells → excess M protein → downstream effects — lets you reason through novel vignettes rather than pattern-match to memorized facts.

From real student decks
86%have cards covering this topic
70%have mature cards

Common misconceptions

Common mistake
Wrong: Multiple myeloma always produces IgG and that IgA or light-chain-only variants are rare exceptions not worth knowing.
Right: Multiple myeloma most commonly produces IgG (~55%), but IgA (~25%) and light-chain-only disease are well-tested variants with distinct features.
IgG is the most common subtype (~55%), but IgA (~25%) and light-chain-only disease are both heavily tested on USMLE Step 1. Light-chain-only myeloma is seronegative on SPEP but positive on UPEP (Bence Jones protein), which is a classic exam trap. Knowing the distribution and the serum-vs-urine testing implications for each variant is essential, not optional.
Common mistake
Wrong: The hypercalcemia in myeloma is caused by PTH secretion by the tumor.
Right: Myeloma hypercalcemia is caused by osteoclast activation via RANKL/IL-1/IL-6 from tumor cells, not PTH secretion.
PTH has nothing to do with myeloma hypercalcemia — PTH would actually be suppressed in a high-calcium state. The real mechanism is that myeloma cells secrete cytokines (RANKL, IL-1, IL-6) that activate osteoclasts, which resorb bone and release calcium. This is why myeloma produces lytic lesions without osteoblastic reaction — the osteoclasts are doing all the work.
Common mistake
Wrong: Rouleaux formation on smear is a specific diagnostic finding unique to myeloma.
Right: Rouleaux formation reflects elevated paraprotein causing RBC stacking and is seen in any condition with markedly elevated globulins, not exclusively myeloma.
Rouleaux (RBC stacking on smear) is a physical consequence of elevated protein in plasma reducing the normal electrostatic repulsion between red cells — it happens in any condition with markedly elevated immunoglobulins or fibrinogen. It's a useful clue in context, but you can also see it in Waldenström macroglobulinemia, chronic inflammation, and other hyperglobulinemic states. Never call it pathognomonic for myeloma.
Common mistake
Wrong: Myeloma patients are immunocompromised primarily because of neutropenia from marrow replacement.
Right: The dominant immune defect in myeloma is hypogammaglobulinemia (normal Ig suppression by the clone), making encapsulated bacterial infections the primary risk even before chemotherapy.
Neutropenia is a treatment complication, not the primary immune defect of myeloma itself. The clonal plasma cells suppress normal polyclonal immunoglobulin production, resulting in hypogammaglobulinemia — meaning the patient can't make adequate antibodies against encapsulated bacteria like S. pneumoniae and H. influenzae. This is why pneumonia is the most common infection in myeloma patients at presentation, before any chemotherapy is given.
Common mistake
Wrong: The amyloidosis complicating myeloma is AA (serum amyloid A) type.
Right: Myeloma-associated amyloidosis is AL type, derived from immunoglobulin light chains (lambda > kappa).
AA amyloid is derived from serum amyloid A, an acute-phase reactant — it's the type associated with chronic inflammatory diseases like rheumatoid arthritis and IBD. Myeloma produces AL amyloid, which is made from immunoglobulin light chains (most often lambda). AL amyloid deposits in kidney (nephrotic syndrome), heart (restrictive cardiomyopathy), and peripheral nerves. Getting the type right is critical because the mechanism, associations, and organ involvement differ.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Diagnostic criteria: what combination of bone marrow biopsy findings, SPEP/UPEP results, and immunoglobulin class establishes the diagnosis of multiple myeloma versus MGUS or smoldering myeloma.
  2. CRAB end-organ damage: how to recognize and mechanistically explain hypercalcemia, renal failure, anemia, and bone lesions as consequences of the plasma cell clone — and why these features define active myeloma requiring treatment.
  3. Smear and lab interpretation: recognizing rouleaux formation and markedly elevated ESR in context, knowing these reflect hyperglobulinemia (not myeloma-specific), and understanding why these patients are susceptible to encapsulated bacterial infections via hypogammaglobulinemia.
  4. Complications: identifying amyloidosis as AL type (light-chain derived, not AA), distinguishing hyperviscosity syndrome from other causes, and knowing that lytic bone lesions can cause pathologic fractures and spinal cord compression.

Can you avoid these mistakes?

A 68-year-old man presents with back pain, serum calcium of 12.5 mg/dL, creatinine of 2.8 mg/dL, and hemoglobin of 8.1 g/dL. SPEP shows a large M spike. What is the most likely immunoglobulin class, and what does a negative SPEP with positive UPEP tell you about the variant?
A patient with known multiple myeloma develops nephrotic syndrome and a restrictive pattern on echocardiography. What type of amyloid is responsible, what is it derived from, and how does this differ from the amyloid seen in a patient with longstanding rheumatoid arthritis?
On a peripheral blood smear from a patient with multiple myeloma, you notice RBCs stacked like coins. A medical student says this finding is diagnostic of myeloma. How would you correct them, and what is the actual mechanism behind this finding?
A myeloma patient not yet on chemotherapy presents with recurrent pneumococcal pneumonia. What is the primary mechanism of immunosuppression in untreated myeloma, and why does this predispose specifically to encapsulated bacteria rather than opportunistic fungi or viruses?

Related topics

Hematopoiesis and Lineage Differentiation RBC Physiology and Lifespan WBC Differential and Function Platelet Physiology and Primary Hemostasis

See how your Anki deck covers this topic.

Upload your deck for a free audit →